Where this fits in the wider picture BPC-157 sits in the regenerative-research family alongside TB-500, GHK-Cu, and Thymosin Alpha-1
Injectable delivery provides enhanced bioavailability and deeper tissue penetration, making it suitable for more significant regenerative goals
By eliminating senescent cells in preclinical systems, FOXO4-DRI indirectly reduces the source of SASP factors
The Grey Market Problem A quick internet search for "BPC-157" returns dozens of websites selling peptides under the guise of "research use only." These vendors operate in a regulatory grey area, selling peptides technically labeled for research but clearly marketed toward human use
For preemptive analgesia, 4 mg/kg of carprofen was given once just before surgery and continued every 24 hours for 3 days postoperatively [2]
The research on NMN in dogs and cats is nearly nonexistent, though one small-scale, short-duration study including beagles illustrated that doses as high as 1,340mg/day may be safe.18 Thats not exactly a resounding endorsement for efficacy